TirzTom said:The pharmacokinetics explain nearly every practical question asked here.
This is where I part company with the consensus forming above. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.
Adding the numbers, since they settle part of this. Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about five days for tirzepatide, steady state at four to five half-lives, subcutaneous bioavailability high enough that site choice is irrelevant.
CarlaRPh_TPA said:This treats a plausible mechanism as a demonstrated one.
Adding the part of the answer the thread has not reached. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemA narrower follow-up, since the general answer is now clear:
Which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working?
OP back with an update, since a thread like this is useless without one.
Closing this out: the trough rather than the peak explains the pattern I was seeing on day six, which I had been blaming on the vial.